For decades, Albania’s public health sector has struggled with the supply and quality of the drugs available on the market.  According to a World Bank report published in June 2014, public spending on healthcare in Albania accounts for only 2.6 per cent of GDP, the lowest rate in the region. At the same time, private spending on healthcare is equivalent to 3.4 per cent of GDP, the highest rate in the region. The health sector in Albania is developing through a recently approved project on Health System Improvement, which is focused on improving the efficiency and quality of health care. The project seeks to strengthen the management and governance of public hospital services, improve health financing arrangements, and establish health information systems.

For decades the public health sector of Albania fought for the quality of drugs available on the market.

Companies providing services in the area of pharma regulatory affairs in Albania, work with such regulatory body as the Albanian Institute of public health. This institution keeps all statistics in health area.

The regulator mission is informatization, standardization and aggregation of data on health, publishing data on the demographic situation, morbidity, healthcare system, and other information.

In Albania there are two lists of reimbursement:

The list of drugs subject to reimbursement, and the list of categories of medicines, the cost of which is non-refundable.

Fully refunded are: the cost of essential drugs (e.g., drugs for cancer, antibiotics, medicines for cardiovascular system diseases), and very expensive drugs and vaccines that are included into the national vaccination program.

Albanian health sector develops within the framework of recently approved health system improvement project, which aims to improve  efficiency and quality of healthcare. The project aims to strengthen public hospital services management, improvement of health financing mechanisms, and establishment of health information system.

Companies providing services in the area of regulatory affairs will help pharmaceutical companies to bring their products to the markets of Albania and Eastern Europe.